Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinica...( - Progression-Free Survival Data to b...),Health

- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials -

- Company to Hold Investor Event on Sunday, May 31 with Oncology Experts -

SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present new data from two ongoing Phase 2 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. The Company will present results of picoplatin plus docetaxel/prednisone in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC) and picoplatin plus 5-FU/leucovorin in patients with metastatic colorectal cancer (CRC).

Both presentations will include new, recently obtained, efficacy and safety data, including progression-free survival data, not reflected in the abstracts that will be posted on the ASCO Web site on Thursday, May 14 at 6:00 p.m. Eastern Time. The CRC presentation will be followed by an ASCO poster discussion.

Poster presentation details are as follows:

    --  Results of a Phase II study of picoplatin with docetaxel and
        prednisone in first-line treatment of castration-resistant prostate
        cancer
        Abstract #5140
        R. De Jager, L. Roman, N. Lopatkin, P. Karlov, H. Breitz, R. Earhart
        General Poster Session: Sunday, May 31, from 2:00 p.m.-6:00 p.m.
         Eastern Time
        Level 2, West Hall C, Poster #J6

    --  Randomized Phase II study of picoplatin in combination with
        5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing
        alternative to modified FOLFOX-6 as first-line therapy for colorectal
        cancer
        Abstract
'/>"/>
SOURCE  Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 
Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial